A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Overweight or Obesity, CKD, Type 2 Diabetes
About this trial
This is an interventional treatment trial for Overweight or Obesity
Eligibility Criteria
Inclusion Criteria: Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²) Have either no T2D with an HbA1c <6.5% (<48 mmol/mol) or have T2D with an HbA1c 10.5% (≤91 mmol/mol), and treated with diet and exercise only with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin. Are on stable treatment, for at least 90 days before screening. Have been diagnosed with chronic kidney disease (CKD). Exclusion Criteria: Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening. Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting of U500 Insulins Have a prior or planned surgical treatment for obesity Have Type 1 Diabetes (T1D) Have acute or chronic hepatitis Have a history of malignant disease within 5 years before screening.
Sites / Locations
- The Institute for Liver Health dba Arizona Clinical Trials
- Hope Clinical Research, Inc.Recruiting
- Catalina Research Institute, LLCRecruiting
- Peninsula Research AssociatesRecruiting
- Suncoast Clinical Research, Inc.Recruiting
- Prime Health and Wellness/SKYCRNG
- Victorium Clinical Research - HoustonRecruiting
- Endocrine Ips, PllcRecruiting
- Tranquility Research
- Circulate Cardiac & Vascular CentreRecruiting
- North York Diagnostic and Cardiac CentreRecruiting
- Stouffville Medical Centre
- Dr. Anil K. Gupta Medicine Professional Corporation
- Fadia El Boreky MedicineRecruiting
- Viacar Recherche CliniqueRecruiting
- 9109-0126 Quebec Inc.Recruiting
- Centro Cardiologico Monzino
- Azienda Ospedaliera Universitaria Pisana
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
- Ospedale San Raffaele
- Hospital Universitario Doctor Peset
- Hospital Clinico de Valencia
- Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
- Vascular Research Team
- North Middlesex Hospital
- City Hospital, Nottingham University Hospitals
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
LY3437943
Placebo
Participants will receive multiple doses of LY3437943 subcutaneously (SC)
Participants will receive LY3437943